Presbyopia-Correcting Intraocular Lens Improves Vision Outcomes
.jpg?width=1200)
MONDAY, Sept. 22, 2025 -- Patients implanted with the TECNIS PureSee extended depth of focus (EDF) presbyopia-correcting intraocular lens (PCIOL) have excellent or good vision, according to a study presented at the European Society of Cataract and Refractive Surgeons Congress, held from Sept. 12 to 16 in Copenhagen, Denmark.
Oliver Findl, M.D., from Hanusch Hospital in Vienna, and Diana Cheng, from Johnson & Johnson MedTech in Irvine, California, conducted a multicenter observational study involving patients bilaterally implanted with the TECNIS PureSee EDF PCIOL. Reports included postoperative manifest refraction spherical equivalent (MRSE), patient-reported outcomes, best-corrected distance visual acuity (BCDVA), distance-corrected intermediate VA (DCIVA), and distance-corrected near VA (DCNVA).
At the time of presentation, data were included for 238 patients. The researchers found that mean MRSE was 0.01 ± 0.39 D, while mean logMAR binocular BCDVA, DCIVA, and DCNVA were –0.05 ± 0.09, 0.11 ± 0.10, and 0.22 ± 0.16, respectively. A logMAR of 0.2 or better DCIVA was achieved by 92 percent of individuals binocularly, and 78 percent achieved 0.3 logMAR or better DCNVA. For distance, intermediate, near, and overall vision, a high percentage of patients reported not needing glasses or needing glasses a little of the time (96, 93, 62, and 85 percent, respectively), while 96, 94, 73, and 95 percent were mostly or completely satisfied with their distance, intermediate, near, and overall vision, respectively. Most (96 percent) would recommend the lens to their family and friends.
"The category of EDF IOLs, such as the TECNIS PureSee, are a great alternative to multifocal lenses for patients who wish to be less dependent on spectacles after lens surgery and do not want to take the risk of unwanted optical side effects," Findl said in a statement.
The study was funded by Johnson & Johnson MedTech.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Pilocarpine-Diclofenac Eye Drops Tied to Improvement in Presbyopia
TUESDAY, Sept. 16, 2025 -- For presbyopia management, pilocarpine-diclofenac eye drops provide dose-dependent improvement, which can be sustained over two years, according to a...
Self-Sufficiency Regained Immediately in Most Patients After Simultaneous Bilateral Cataract Surgery
TUESDAY, Sept. 16, 2025 -- Most patients can manage at home without help after bilateral cataract surgery, with as good or better visual outcomes, according to two studies...
AI Algorithm Predicts Progression of Keratoconus
TUESDAY, Sept. 16, 2025 -- An artificial intelligence (AI) algorithm can predict progression of keratoconus, according to a study presented at the annual Congress of the European...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.